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HOW THE GOVERNMENT CREATED AND SUSTAINS THE 
PRIVATE PHARMACEUTICAL INDUSTRY 
ROBERT I. FIELD* 
I.  INTRODUCTION 
The private pharmaceutical industry is perennially one of the most 
profitable in the United States.1 Its success is built on a cascade of products, 
some of which generate billions of dollars in sales each year.2 New ones 
continually enter the market to replenish the supply. 
Companies that ultimately market new drugs are visible to all. Their 
partners in research and clinical testing are known in the industry and 
throughout the investment community. What is not as readily apparent is the 
partner that creates the foundation for the entire drug development process. 
That is the government.3 
New drugs emerge from many different sources. Some come from 
research that applies basic biological knowledge.4 Some emerge from trial 
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 1. Uwe E. Reinhardt, Perspectives on the Pharmaceutical Industry, HEALTH AFF., Sept. – 
Oct. 2001, at 142-43. 
 2. See, e.g., PHARM. RESEARCH & MFRS. OF AM., PHARMACEUTICAL INDUSTRY PROFILE 2010, 
at 50 tbl.8 (2010). 
 3. Iain M. Cockburn & Rebecca M. Henderson, Absorptive Capacity, Coauthoring 
Behavior, and the Organization of Research in Drug Discovery, 46 J. INDUS. ECON. 157, 160 
(1998); Benjamin Zycher et al., Private Sector Contributions to Pharmaceutical Science: Thirty-
Five Summary Case Histories, 17 AM. J. THERAPEUTICS 101, 103 (2010). 
 4. See PHARM. RESEARCH & MFRS. OF AM., supra note 2, at 33. 
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and error.5 Others materialize from serendipity when they are least 
expected.6 
It is a long and expensive path from the initial conjecture that a 
substance may have clinical potential to its ultimate entry into the market.7 
The path has countless twists and turns, and many journeys do not succeed.8 
When one does, a single player rarely travels the entire road alone.9 
Whatever the initial source of discovery, multiple partners usually join the 
effort, and they come from both the public and private spheres.10 
Few would dispute the value of government-funded research as the 
foundation of drug discovery. Even the most ardent admirers of private 
industry innovation concede the importance of the government in promoting 
the underlying science on which it rests.11 Debates may rage over the 
relative amount of credit that each side deserves, but not over the necessity 
of both sectors to the advancement of pharmaceutical science. 
Most of the drugs in wide use today resulted from such public-private 
collaborations. Of the 21 drugs with the highest therapeutic impact, 14 
stemmed directly from an enabling discovery that the government had 
supported.12 Often, public and private research continues to interact even 
after a new drug therapy has reached the market.13 Such continuing 
interchanges have produced major breakthroughs, for example better 
understanding of the mechanism of action of Azidothymidine (AZT) as a 
treatment for HIV infection.14 
However, the public-private partnership does not end with a handoff 
from government-backed basic scientists to applied investigators in 
corporate settings. The public sector contributes to drug development 
throughout the lifecycle of new drugs in many ways.15 Perhaps most 
significantly, it creates vast markets for drugs through public health 
 
 5. Stefan Thomke et al., Modes of Experimentation: An Innovation Process - and 
Competitive - Variable, 27 RES. POL’Y 315, 324 (1998). 
 6. Thomas A. Ban, The Role of Serendipity in Drug Discovery, 8 DIALOGUES CLINICAL 
NEUROSCIENCE 335, 342 (2006). 
 7. PHARM. RESEARCH & MFRS. OF AM., supra note 2, at 27. 
 8. Id. at 27-28. 
 9. See id. at 33. 
 10. See id. 
 11. Zycher et al., supra note 3, at 102. In this study, the authors seek to demonstrate the 
value of industry research and development in bringing important new drugs to patients. Id. at 
105. They begin their analysis by observing, “the importance of government-funded research, 
particularly in terms of the science of disease processes and applications to pharmacologic 
advances, is not in dispute.” Id. at 103. 
 12. Zycher et al., supra note 3, at 105, 116. 
 13. See Cockburn & Henderson, supra note 3, at 160. 
 14. Zycher et al., supra note 3, at 112. 
 15. Cockburn & Henderson, supra note 3, at 160. 
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insurance programs. Medicare, which insures the elderly, spends over $55 
billion a year on outpatient prescriptions, and over $10 billion on drugs 
administered by physicians.16 Medicaid, which insures the poor, spends over 
$26 billion a year.17 The government also purchases drugs for veterans 
through the Veterans Health Service and through the Department of Defense 
for military personnel and their dependents.18 
The government also shapes the pharmaceutical industry through 
regulation. The primary agency involved is the Food and Drug 
Administration (FDA), which serves as a gatekeeper to determine which 
drugs may reach the market.19 To pass through the gate, new products must 
undergo years of clinical testing that assess safety and effectiveness.20 After 
approval, the FDA continues to monitor drugs for safety and to impose 
restrictions on marketing and promotion.21 The FDA-imposed testing 
process accounts for the lion’s share of the cost of drug development and 
sets parameters for the kinds of drugs that ultimately reach patients.22 While 
manufacturers may complain about bureaucratic inefficiency and delays on 
the agency’s part, this vetting process is largely responsible for the public’s 
confidence in their products.23 
Beyond the FDA, patent laws, administered by the United States Patent 
and Trademark Office (USPTO), circumscribe the commercialization and 
marketing process.24 Patent rules determine the nature and length of the 
 
 16. MEDICARE PAYMENT ADVISORY COMM’N, A DATA BOOK, HEALTHCARE SPENDING AND THE 
MEDICARE PROGRAM 169 (2010), available at www.medpac.gov/documents/jun10databook 
entirereport.pdf; see KAISER FAMILY FOUND., MEDICARE SPENDING AND FINANCING FACT SHEET 1 
(2010), available at http://www.kff.org/medicare/upload/7305-05.pdf [hereinafter KAISER 
FAMILY FOUND., MEDICARE SPENDING]. 
 17. JOHN HOLAHAN ET AL., KAISER FAMILY FOUND., MEDICAID SPENDING GROWTH OVER THE 
LAST DECADE AND THE GREAT RECESSION, 2000-2009 at 8, 10 (2011), available at 
www.kff.org/medicaid/upload/8152.pdf. 
 18. CONG. BUDGET OFFICE, PUB. NO. 3016, THE HEALTH CARE SYSTEM FOR VETERANS: AN 
INTERIM REPORT 1 (2007); TRICARE Facts and Figures, TRICARE (March 2012), http://www.tri 
care.mil/pressroom/press_facts.aspx. 
 19. SUSAN THAUL, CONG. RESEARCH SERV., R41983, HOW FDA APPROVES DRUGS AND 
REGULATES THEIR SAFETY AND EFFECTIVENESS 1 (2012). 
 20. The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, U.S. FOOD & 
DRUG ADMIN. (May 1, 2012), http://www.fda.gov/drugs/resourcesforyou/consumers/ucm 
143534.htm. 
 21. THAUL, supra note 19, at 8. 
 22. See Joseph A. DiMasi et al., The Price of Innovation: New Estimates of Drug 
Development Costs, 22 J. HEALTH ECON. 151, 167 (2003). 
 23. ROBERT I. FIELD, HEALTH CARE REGULATION IN AMERICA: COMPLEXITY, CONFRONTATION, 
AND COMPROMISE 139 (2007); Dale H. Gieringer, The Safety and Efficacy of New Drug 
Approval, 5 CATO J. 177, 177, 178 (1985). 
 24. See F.M. Scherer, The Pharmaceutical Industry – Prices and Progress, 351 NEW ENG. 
J. MED. 927, 927-28 (2004). 
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monopoly granted to new drugs, which is what makes them profitable to 
develop.25 These rules are supplemented by a number of related laws that 
further refine the contours of the pharmaceutical market. These include the 
Drug Price Competition and Patent Term Restoration Act,26 commonly 
known as the Hatch-Waxman Act, which structures the market for generic 
competition, and the Food and Drug Administration Modernization Act 
(FDAMA),27 which extends monopoly protection for drugs that are tested on 
children. 
II.  AMERICA’S ROBUST DRUG COMPANIES 
A. Perennial Profitability 
Over the past 20 years, no American industry has outperformed 
pharmaceutical manufacturing in terms of profitability. According to the 
most widely used measures, drug companies earned three times the median 
of all Fortune 500 companies in 2004 and over five times the median in 
2001.28 Between 1995 and 2002, pharmaceutical manufacturing was the 
most profitable industry in the United States, and since then it has remained 
in the top three every year.29 The rate of return on investment consistently 
hovers near 20%, a figure that most other industries can only dream of.30 
Sales of prescription drugs in the United States now exceed $300 billion 
a year.31 Even during the recession year of 2009, sales remained robust, 
growing at a rate of 5.1% from the year before.32 Global sales for 2009 
 
 25. Id. 
 26. Drug Price Competition and Patent Term Restoration (Hatch-Waxman) Act of 1984, 
Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 15, 21, 35, 
42 U.S.C. (2006)). 
 27. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 
111 Stat. 2296 (codified as amended in scattered sections of 21, 26, 42 U.S.C. (2006)). 
 28. Trends and Indicators in the Changing Health Care Marketplace, KAISER FAMILY 
FOUND. (Feb. 8, 2006), http://www.kff.org/insurance/7031/ti2004-1-21.cfm. 
 29. MICHELE BOLDRIN & DAVID K. LEVINE, AGAINST INTELLECTUAL MONOPOLY 256 (2008); 
KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS 4 (2010), available at http://www.kff.org/rx 
drugs/upload/3057-08.pdf [hereinafter KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS]. 
 30. Reinhardt, supra note 1, at 136, 142. 
 31. IMS INST. FOR HEALTHCARE INFORMATICS, THE USE OF MEDICINES IN THE UNITED STATES: 
REVIEW OF 2010, at 4 (2011), available at http://www.imshealth.com/deployedfiles/imshealth/ 
Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf. 
 32. Id. 
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stood at $837 billion after rising 7% from a year earlier.33 Both domestically 
and globally, these rates continue to accelerate.34 
B. The Financial Engine:  Research and Development 
Several factors account for the pharmaceutical industry’s consistent 
good fortune.35 For one, demand for health-enhancing and life-saving 
products will never diminish, so the industry’s output will always be 
needed.36 For another, most consumers today have assistance from third 
parties in paying for pharmaceutical products through some form of 
insurance, either public or private.37 
The pharmaceutical industry is also able to charge high prices for many 
of its products because they are insulated from market competition through 
patents.38 While patents do not last indefinitely, they, along with various 
other legal protections, offer most prescription drugs at least 10 years of 
market exclusivity after they first reach consumers and often more.39 
The exclusive sale of life-saving products is certainly a recipe for 
financial success, but only if one more ingredient is present. As patents 
expire, competitive pricing by manufacturers of generic copies drives down 
profit margins, so a steady supply of new drugs is needed.40 The industry 
must devote a tremendous amount of its attention and resources to that end. 
To maintain profitability, a steady supply of fresh products must continually 
flow through each company’s “pipeline.”41 
 
 33. Biopharma Forecasts & Trends, IMS INST. (2012), http://www.imshealth.com/portal/ 
site/ims/menuitem.d248e29c86589c9c30e81c033208c22a/?vgnextoid=4b8c410b6c7182
10VgnVCM100000ed152ca2RCRD&vgnextfmt=default. 
 34. Id. 
 35. The appropriate accounting for pharmaceutical profitability is somewhat 
controversial. Some analysts believe that the treatment of research and development costs in 
standard assessments is incorrect. Scherer, supra note 24, at 929. They contend that it should 
be treated as an investment subject to depreciation rather than an expense. Id. This approach 
generates much lower rates of profits in comparison to assets. Id. Nevertheless, the resulting 
profitability is still consistently higher than the average for all American industries. Id. 
 36. See NNE Pharmaplan, Biopharmaceuticals: Entering a New World, ANGLE, April 
2012, at 5, 39. “As the global population grows and life expectancy rises, 
biopharmaceuticals are in ever greater demand for the treatment of life-threatening and 
chronic diseases.” Id. at 5. 
 37. See KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS, supra note 29, at 5. 
 38. See Scherer, supra note 24, at 927. 
 39. Id. 
 40. Id. at 929. 
 41. ROY LEVY, THE PHARMACEUTICAL INDUSTRY: A DISCUSSION OF COMPETITIVE AND ANTITRUST 
ISSUES IN AN ENVIRONMENT OF CHANGE, BUREAU OF ECON. STAFF REPORT, FED. TRADE COMM’N 
(March 1999). 
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The never-ending search for new products has shaped the 
pharmaceutical industry into the most research-intensive in the United 
States.42 It devotes more private resources to scientific investigation than any 
other.43 In 2002, this investment equaled 18% of sales, which is roughly five 
times the average for American manufacturing firms.44 Since 1985, this 
percentage has been higher even than that devoted by the computer 
industry.45 
The exact magnitude of pharmaceutical research and development 
spending is subject to some dispute. The industry’s trade association, the 
Pharmaceutical Research and Manufacturers of America (PhRMA) uses a 
broad definition that includes spending on post-market monitoring of drugs 
after their final approval by the FDA.46 By this measure, research spending 
grew from $6 billion to $39 billion between 1980 and 2004 in constant 
2005 dollars, reflecting an average rate of increase of about 8%.47 PhRMA 
puts the 2009 figure at $65.3 billion.48 The National Science Foundation 
(NSF) calculated the value of industry research at the premarket phases only 
and found an increase from $5.5 billion to $17 billion over the same 
period, for an average rate of growth of 5%.49 Nevertheless, under either 
analysis, the industry has steadily and dramatically expanded its commitment 
to research over a considerable period of time. 
Of course, not all of this research activity actually creates new drugs that 
are truly innovative. About two-thirds of the new drug applications (NDAs) 
submitted to the FDA each year do not involve a new molecular entity 
(NME).50 Instead, they represent reformulations or minor modifications of 
existing drugs or requests for approval of new uses.51 Drugs involving 
reformulations or incremental modifications of existing modifications are 
commonly known as “me-too” drugs, as they follow an established 
therapeutic approach.52 In most years, the FDA approves only about 20 
drugs that are based on new NMEs.53 
 
 42. Scherer, supra note 24, at 927. 
 43. CONG. BUDGET OFFICE, PUB. NO. 2589, RESEARCH AND DEVELOPMENT IN THE 
PHARMACEUTICAL INDUSTRY 7 (2006) [hereinafter CONG. BUDGET OFFICE, R&D]. 
 44. See id. at 10 fig.2-2. 
 45. Id. 
 46. PHARM. RESEARCH & MFRS. OF AM., supra note 2, at 41. 
 47. CONG. BUDGET OFFICE, R&D, supra note 43, at 7. 
 48. PHARM. RESEARCH & MFRS. OF AM., supra note 2, at b. 
 49. CONG. BUDGET OFFICE, R&D, supra note 43, at 7. 
 50. Id. at 2. 
 51. Id. at 14-15. 
 52. Id. at 2. 
 53. Id. at 3. 
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However, regardless of the originality of the drugs being introduced, the 
steady flow of new products is a hallmark of the pharmaceutical industry. 
One can debate how much clinical value is actually contributed when new 
drugs mimic existing ones, but it is undeniable that the industry as we know 
it today thrives on a massive research and development apparatus. It is in 
this regard that the government provides it with the biggest boost. 
III.  THE CORNERSTONE OF PUBLIC BIOMEDICAL RESEARCH:  NIH 
How does the industry find the new drugs it needs to refresh its 
inventory? For two-thirds of its products, the answer is easy as they are me-
too drugs based on established products.54 For the one-third of new drugs 
that represents true innovation, the answer is more complex. These are 
medications that are truly new and that emerge from advances in scientific 
knowledge.55 This is where the implicit partnership with the government is 
most essential. 
A. A Mission to Underwrite Biomedical Science 
The government’s foundational role in promoting biomedical research is 
administered primarily by the National Institutes of Health (NIH). This 
massive agency, which is a component of the United States Department of 
Health and Human Services, spends about $30 billion a year to enhance 
the fundamental understanding of biology and medicine.56 That amount has 
more than doubled since the mid-1990s.57 Most of it is devoted to basic 
science that seeks to decipher underlying physiological mechanisms — the 
raw fuel that private companies refine into finished commercial products.58 
The division of research roles between industry and government is not a 
simple split between applied and basic science. NIH performs some applied 
clinical studies of new drugs, and private industry conducts some basic 
research.59 The relationship between the private and public spheres is further 
blurred by a range of other government programs that promote the 
 
 54. CONG. BUDGET OFFICE, R&D, supra note 43, at 2. 
 55. Id. at 7. 
 56. NIH Almanac, Appropriations (Section 2), NAT’L INSTS. OF HEALTH (March 6, 2012), 
http://www.nih.gov/about/almanac/appropriations/part2.htm [hereinafter NIH Almanac]. 
 57. Id. 
 58. Department of Health and Human Services, National Institutes of Health Fiscal Year 
2013 Budget Request: Hearing Before the H. Subcomm. on Labor – HHS – Education 
Appropriations, 112th Cong. 4-5 (2012) (statement of Francis S. Collins, Director, National 
Institutes of Health). 
 59. CONG. BUDGET OFFICE, R&D, supra note 43, at 3. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
18 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 6:11 
translation of NIH-funded research into commercial uses.60 However, in all 
of these endeavors, the two sectors follow a similar pattern of partnership to 
produce new medicines.61 
The importance of government-sponsored research to pharmaceutical 
industry vitality cannot be overstated. One analysis estimated that every 1% 
increase in public research funding produces an increase of between 2 and 
2.4% in the number of commercially available new compounds.62 Another 
projected the rate of return from public funding of biomedical research at 
up to 30% a year.63 Without question, government-funded science is an 
essential ingredient underlying the industry’s business model. 
B. NIH’s Growth from Humble Origins 
The huge scientific enterprise that NIH represents today began as a 
modest endeavor in the late nineteenth century in Staten Island, New York.64 
Dr. Joseph J. Kinyoun set up a laboratory in a marine hospital there in 1887 
to study bacteria that cause common infectious diseases.65 He succeeded in 
identifying the organism that causes cholera, the cholera bacillus, which 
aided physicians in diagnosing suspicious cases of this deadly disease.66 
Successes such as this led the government to move his laboratory in 1891 to 
Washington, D.C. and to give it a new name, the Hygienic Laboratory.67 
Ten years later, Congress authorized $35,000 for a new building to house 
it.68 
The Hygienic Laboratory gained new responsibilities and prominence in 
1902, when Congress created a Division of Pathology and Bacteriology 
within the federal Marine Hospital Service to house its research.69 At that 
time, the laboratory also added Ph.D.-trained researchers to the physicians 
in its workforce.70 Among its new responsibilities was setting standards and 
 
 60. See ANDREW A. TOOLE, STANFORD INST. FOR ECON. POLICY RESEARCH, THE IMPACT OF 
PUBLIC BASIC RESEARCH ON INDUSTRIAL INNOVATION: EVIDENCE FROM THE PHARMACEUTICAL 
INDUSTRY 9 (2000). 
 61. See id. at 12-13. 
 62. Id. at 5. 
 63. Iain M. Cockburn & Rebecca M. Henderson, Publicly Funded Science and the 
Productivity of the Pharmaceutical Industry, in 1 INNOVATION POLICY AND THE ECONOMY 1, 28 
(Adam B. Jaffe et al. eds., 2001). 
 64. Victoria A. Harden, A Short History of the National Institutes of Health, NAT’L INSTS. OF 
HEALTH OFFICE OF NIH HISTORY (2005), http://history.nih.gov/exhibits/history/index.html. 
 65. Id. 
 66. Id. 
 67. Id. 
 68. Id. 
 69. Harden, supra note 64. 
 70. Id. 
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issuing licenses for the manufacture of vaccines and antitoxins by private 
companies, a role that was included in the Biologics Control Act, passed 
that year.71 This responsibility was eventually transferred to the FDA in 
1972.72 Along with this new regulatory authority came an expanded mission 
of research to support it.73 
Another round of important scientific discoveries emerged from the 
laboratory in the years leading up to World War I.74 These included such 
practical findings as the link between pellagra and a dietary deficiency and 
between unsanitary conditions around military bases and disease 
outbreaks.75 In recognition of its growing contributions, scientists who 
worked in the laboratory were accepted for the first time as members of the 
executive branch of government.76 In 1912, the agency housing the 
laboratory was renamed the Public Health Service.77 
As the value of biomedical science became increasingly apparent, 
efforts were launched after the War to expand its reach.78 Most notably, a 
group of scientists from a wartime agency, the Chemical War Service, 
sought industry funding to support research into applications of chemistry to 
medicine.79 However, several years of trying yielded no success in attracting 
private sponsors.80 
In 1926, the scientists gave up their quest to find funding in the private 
sector and turned to Congress, instead.81 They found a champion in Senator 
Joseph E. Ransdell of Louisiana, who in 1930 successfully sponsored 
legislation to fund fellowships for basic research within the Hygienic 
Laboratory.82 The Ransdell Act also changed the name of the laboratory to 
the National Institute of Health.83 Initial funding was modest, but it marked 
the start of a new approach to the sponsorship of research under 
government auspices.84 Funding grew significantly over the years along with 
 
 71. Id. 
 72. Id. 
 73. Id. 
 74. Harden, supra note 64. 
 75. FIELD, supra note 23, at 207. 
 76. VICTORIA A. HARDEN, INVENTING THE NIH: FEDERAL BIOMEDICAL RESEARCH POLICY, 1887-
1937, at 3 (1986). 
 77. Harden, supra note 64. 
 78. See FIELD, supra note 23, at 207-08. 
 79. Harden, supra note 64. 
 80. Id. 
 81. Id. 
 82. Ransdell Act, Pub. L. No. 71-251, 46 Stat. 379 (1930) (codified as amended at 42 
U.S.C. §§ 21, 22, 23a–23g (2006)). 
 83. Harden, supra note 64. 
 84. Id. 
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the Institute’s mission, and the name was pluralized in 1948 to recognize a 
more diverse role.85 
C. Expansion into a Research Powerhouse 
NIH is organized today into 27 component institutes that focus on 
specific categories of diseases or types of therapy.86 Each employs scientists 
in-house to work in government laboratories but spends most of its 
resources funding researchers outside of the government in universities and 
research institutes.87 The model for this structure originated in 1937 with the 
establishment of the National Cancer Institute (NCI).88 Originally organized 
as an independent agency, it was formally incorporated into NIH in 1944.89 
The intramural research component of NIH’s mission gained a major 
boost in 1940, when the agency opened its sprawling campus in Bethesda, 
Maryland.90 The land was donated by Mr. and Mrs. Luke Wilson, and today 
it houses one of the largest collections of scientific research buildings in the 
world.91 In 1953, a large hospital, the Warren Grant Magnuson Clinical 
Center, was added to the site.92 When he dedicated the complex, President 
Franklin Roosevelt emphasized the significance of the enterprise to national 
security on the eve of America’s entry into World War II. He observed:  “We 
must recruit not only men and materials but also knowledge and science in 
the service of national strength and that is what we are doing here.”93 
If anyone doubted the value of biomedical science to military strength at 
the time, World War II would have removed any uncertainty. As one 
observed noted, the war effort “had mobilized a concerted government 
effort — unprecedented to date — in applying research to practical use.”94 
America’s success in the War owed a huge debt to a long list of medical 
 
 85. See FIELD, supra note 23, at 208. 
 86. About NIH, NAT’L INSTS. OF HEALTH (Aug. 7, 2012), http://www.nih.gov/about/ 
[hereinafter About NIH]. 
 87. NIH Budget, NAT’L INSTS. OF HEALTH (March 1, 2012), http://www.nih.gov/about/ 
budget.htm. 
 88. Harden, supra note 64. 
 89. Id. 
 90. The NIH Almanac—Historical Data, NAT’L INSTS. OF HEALTH (March 27, 2012), 
http://www.nih.gov/about/almanac/historical/chronology_of_events.htm. 
 91. Carla Garnett, Last of ‘Treetops,’ Bldg. 15K Is Refurbished, NAT’L INSTS. OF HEALTH 
RECORD (May 29, 2001), http://nihrecord.od.nih.gov/newsletters/05_29_2001/story01.htm. 
 92. Harden, supra note 64. 
 93. Franklin Delano Roosevelt, The Dedication of the National Institutes of Health, 36 
CLINICAL RESEARCH 1, 1-2 (1988). 
 94. JUDITH ROBINSON, NOBLE CONSPIRATOR: FLORENCE S. MAHONEY AND THE RISE OF THE 
NATIONAL INSTITUTES OF HEALTH 59 (2001). 
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advances developed at that time, most of which continue to protect us 
today.95 
The importance of these medical advances was not lost on the public or 
on politicians. As the War ended, NIH received significant new authority to 
maintain its research role.96 Initially, it received responsibility for phasing out 
wartime research contracts with universities, but Congress soon changed 
course and decided that many of these arrangements should remain in 
place.97 The agency continued to administer them, and it received 
additional funding and staff to pursue this mission.98 The Public Health 
Service Act of 1944, which had merged NCI into NIH, provided for the 
creation of additional component institutes, and it set in motion a series of 
dramatic budget increases that have continued ever since.99 An NIH budget 
of $4 million in 1947 grew to $100 million in 1957, to $1 billion in 1974, 
to more than $27 billion in 2004, and to $30 million in 2009.100 
D. NIH as the Backbone of Biomedical Science 
From the perspective of public policy, the most significant aspect of the 
steady NIH budget increases is the portion that is directed to private 
researchers. About 80% of the agency’s budget supports studies at 
universities, research institutes, and similar organizations.101 Scientists in 
these settings propose the actual structure of the studies they wish to 
conduct and the research questions they will pursue.102 The agency then 
constitutes committees of experts from outside of government to determine 
which of these proposals merit funding.103 This arrangement shapes the 
huge research enterprise that the agency supports as a public-private 
partnership on a massive scale. In the words of one observer:  “Never in the 
nation’s history had public funds in such amounts been placed at the 
disposal of individuals working in support of their own objectives outside the 
framework of federal institutions.”104 
Over the years since World War II, the nation has looked to NIH time 
and time again as the first line of attack to address pressing health needs. In 
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1971, President Richard Nixon launched a “war on cancer” by asking 
Congress to expand funding for NCI.105 In the early 1980s, advocates for 
patients with AIDS lobbied Congress to increase support for NIH research 
into the disease’s cause and potential treatments.106 In the late 1990s, 
advocates for patients with Parkinson’s Disease successfully lobbied for 
additional NIH funding for research into that condition.107 
As the nature of medicine has changed, the focus of NIH-sponsored 
research has evolved along with it. In 1992, the agency added the National 
Center for Complimentary and Alternative Medicine, and in 1993, the 
National Center on Minority Health and Health Disparities.108 With all of 
these changes in funding priorities and focus, the goal of Congress and the 
desire of much of the public has been to keep the government in the lead in 
moving American medicine forward.109 
The influence of NIH on biomedical science in America extends well 
beyond its support for individual studies to a role in shaping a key 
foundation of the research enterprise. That is building and maintaining the 
pipeline of new scientists. The agency funds the education of most doctoral 
students in biomedical sciences along with additional postdoctoral training 
that many of them receive.110 Before NIH provided this support, Ph.D.s in 
biomedical science were relatively rare.111 Today, those holding these 
degrees form the workforce that conducts most research that leads to new 
pharmaceutical products. In the words of one observer:  “. . . there is no 
question that the American pharmaceutical and biotechnology industries 
(which lead the world) could not exist, let alone thrive, without those 
thousands of trained people.”112 
E. NIH as the Instigator of Drug Development Collaborations 
When a finding in basic science holds therapeutic promise, NIH does 
not have to wait passively for a private company to express interest. It is 
empowered to proactively seek out a corporate partner to work in 
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partnership to bring a product to market.113 This explicit path to 
collaborative drug development has led to the creation of numerous 
important medications, some of which have revolutionized medical practice 
and brought sizable financial rewards to the private partners involved. 
Among recent successes under these laws are the development of Thyrogen, 
a form of thyroid stimulating hormone commercialized by Genzyme, 
Prezista, a treatment for HIV infection commercialized by Tibotec, and 
Gardasil, a vaccine against the human papilloma virus which can cause 
cervical cancer that is sold by Merck.114 
Congress facilitated the process of forming explicit government-industry 
collaborations with several legislative enactments. It first focused on this 
area in 1980.115 A major impetus was the ruling by the Supreme Court that 
year that permitted the award of patents for artificially engineered life forms 
in the case of Diamond v. Chakrabarty.116 That decision formed the legal 
foundation for the rise of the biotechnology industry by offering investors a 
route to profit from new discoveries.117 
Biotechnology companies seek to commercialize the fruits of academic, 
government and industry research, however the task of coordinating the 
contributions of each of these sectors can be daunting.118 They function in 
separate worlds with vastly different modes of operation. As the nascent 
industry began to take shape, barriers between them threatened to disrupt 
potential synergies that could help it to take off.119 
Congress used several strategies to encourage the growth of the 
biotechnology industry and the commercialization of biomedical discoveries. 
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A simple one was to offer tax credits to companies that conduct research.120 
These have proven quite valuable to industry over time.121 
A more complex strategy with more far-reaching impact was to create a 
framework for building explicit partnerships between the federal government 
and industry. A collection of laws implement strong incentives for companies 
and universities to collaborate with the government to bring scientific 
advances to market. Of these, the Patent and Trademark Law Amendment 
Act of 1980, commonly known as the Bayh-Dole Act, is the most 
important.122 It gives institutions that receive NIH research grants the right to 
patent inventions that flow from the fruits of their investigations.123 The goal 
is to give universities an incentive to attempt to commercialize research 
conducted under their auspices.124 
Despite this incentive, private firms are often reluctant to invest in the 
initial basic research that is needed before actual product development can 
begin.125 To address this gap, Congress developed a mechanism to 
formalize arrangements between government agencies and private entities 
to work jointly on the commercialization of breakthrough technologies. This 
is accomplished through a type of understanding known as a Cooperative 
Research and Development Agreement (CRADA).126 These are partnerships 
that allow for joint development with a negotiated set of contributions, 
responsibilities, and remuneration involving each party.127 
CRADAs are based on a series of laws that Congress enacted during the 
1980s to encourage the transfer of technology from government 
laboratories to private firms that can commercialize it.128 The primary law is 
the Stevenson-Wydler Technology Innovation Act of 1980, which established 
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a set of offices to coordinate technology transfer within each federal agency 
that conducts research.129 In NIH, the office is known as the Office of 
Technology Transfer.130 An amendment to the law enacted in 1986 as part 
of the Technology Transfer Act mandated that the federal government 
actively seek opportunities to transfer technology to industry, academia, or 
state and local governments, rather than passively waiting for them to 
arise.131 This mandate works in tandem with the Bayh-Dole Act, which 
permits private parties to obtain patent rights to the fruits of these efforts.132 
Under a CRADA, the government and the private partner share costs in 
their joint research and development effort.133 Both may contribute 
personnel, services and property, but only the private party may contribute 
money to avoid triggering federal procurement statutes.134 The government 
can grant a license to manufacture and sell the ultimate product to the 
industry partner, or it can simply waive its right of ownership.135 In selecting 
a private partner, the government gives preference to business units located 
in the United States that agree to manufacture any resulting products in the 
county.136 To reassure companies concerned about trade secrets, 
confidential information developed under a CRADA can be protected by the 
government partner from public disclosure for up to five years.137 
F. NIH’s Role in Creating the Future of Medicine 
More recently, NIH has taken an even more proactive role in advancing 
medicine by laying the foundation for the new era of genomics. The agency 
has worked on several fronts to clear a path for this new frontier in 
biomedical science. Its explicit goal is to promote a revolution in the 
understanding of human biology that will lead to products that can be 
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commercialized by private companies.138 The agency’s efforts to expand the 
frontiers of medicine demonstrate more poignantly than any of its initiatives 
in the past the indispensable role that it plays in the vibrancy of the private 
health care sector and in creating the future of the pharmaceutical industry. 
Two of its efforts in this regard are particularly important in nurturing the 
private market as it helps to transform medical science. 
1. The Human Genome Project 
The first of NIH’s efforts to move medicine toward new horizons is the 
immense initiative to map the entire set of human genes known as the 
Human Genome Project (HGP).139 The molecular structure of the genetic 
makeup of all living creatures was discovered in 1953 when James Watson 
and Francis Crick delineated the composition of deoxyribonucleic acid 
(DNA), the chemical building block of genes.140 It was a path-breaking 
discovery that earned the two scientists Nobel Prizes.141 
a. The quest to map the human genome 
Applications of this knowledge were relatively slow to advance for the 
first decades after its discovery.142 That began to change in the 1970s, when 
techniques were developed to manipulate the genetic structure of 
microorganisms.143 With them, the era of custom-designed life forms had 
begun.144 The door to commercialization of these creations was opened in 
1980 with the Supreme Court’s ruling in Diamond v. Chakrabarty that 
artificially created life forms could be patented.145 With legal protection for 
its inventions assured, the biotechnology industry was born. 
Designer microorganisms found an array of uses, but the real promise 
of genetic science lay in its applications to human health. Many diseases 
have been found to have genetic causes, making treatment and prevention 
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by conventional means difficult or impossible.146 By understanding the 
genetic basis for these conditions, scientists foresaw the possibility of curing 
or preventing them by manipulating the actual composition of genes.147 At 
the least, tests could be devised to determine the extent to which individual 
patients were susceptible.148 
During the 1980s, researchers were able to pinpoint the genetic 
mechanisms behind several devastating conditions and in some cases to 
develop tests to diagnose them.149 A major breakthrough along these lines 
was the creation in 1986 of a test for susceptibility to Huntington’s Disease, 
a devastating brain affliction whose occurrence is determined entirely by 
genetic factors.150 However, humans have thousands of genes, and 
interactions between them can be as important in shaping physiological 
effects as their individual composition.151 The full potential of genomic 
medicine could only be realized if the full set of human genes, known as the 
human genome, were delineated. 
Mapping the entire human genome required a massive effort.152 
However, while the possibilities for improving health were enormous, the 
specific applications to which it might lead were speculative.153 This was a 
prime example of basic research with an indeterminate payoff. Once the 
map of the genome had been created, it would be a public good that could 
facilitate research to benefit everyone, but exactly how the map could be 
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applied depended on further research on an applied level.154 As with other 
basic research, the natural sponsor for such a venture was the 
government.155 
Recognizing the potential need, Congress authorized initial funding in 
1988 for a joint effort of the federal Department of Energy (DOE) and NIH 
to map the human genome.156 In 1990, NIH formally launched the HGP 
within a new National Center for Human Genome Research, later renamed 
the National Human Genome Research Institute (NHGRI).157 DOE’s role 
was to promote research into the effects of radiation on genetic 
mutations.158 The HGP relied both on scientists within the government and 
on researchers at numerous external organizations.159 
b. The HGP’s fruits 
The HGP produced a first draft of the genome’s map containing 90 
percent of its contents in 2001 and a final version in 2002 with the entire 
set of genes, several years ahead of schedule.160 The speed was due in part 
to an implicit, and unexpected, collaboration with the private sector.161 To 
pique the interest of private scientists and to help them in joining the effort, 
the HGP in 1996 began placing all findings in a public database within 24 
hours of their disclosure with no limits on their use.162 In 1998, a private 
company, Celera Corporation, took up the challenge of using this 
information by initiating an effort to develop a map of its own.163 A friendly 
competition ensued,164 and it ended with HGP and Celera officials jointly 
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announcing in 2000 that they had completed an initial analysis of the 
genome’s sequence.165 
The HGP’s accomplishment in mapping the entire human genome has 
been called “one of the remarkable achievements in the history of 
science.”166 It is a singular accomplishment of government-funded science 
that promises to revolutionize medical care and with it the entire 
pharmaceutical industry.167 In achieving this milestone, NIH laid the 
foundation for yet another level of pharmaceutical productivity.168 
Of course, mapping the genome is only the first step in bringing the 
promise of genomic medicine to fruition. The next step is to devise 
applications for this new knowledge.169 This step, as the previous one, relied 
on input from both the government and the private sector. Starting in 1993, 
as work on the genome map was proceeding, NIH scientists began 
investigating the function of various genes as soon as they had been 
identified along with their roles in human health and disease.170 Soon 
thereafter, several private companies began doing the same.171 Within ten 
years, several hundred diagnostic tests had been developed, and initial 
experiments had been launched at actual gene therapy in which new genes 
are inserted in patients to replace defective ones.172 
Genomics today is fast becoming a standard part of medical practice in 
several areas. Its effect is particularly pronounced in the field of oncology.173 
In an especially important advance, scientists discovered in the 1990s that 
mutations in two genes that were labeled BRCA1 and BRCA2 significantly 
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increase a woman’s chance of developing breast and ovarian cancer.174 A 
test for these mutations was devised and is now routinely used by clinicians 
to advise women of their cancer risk.175 It is administered by a private 
company, Myriad Genetics, which holds a patent on the genes involved.176 
Myriad’s business of testing for BRCA mutations has proven extremely 
profitable and has attracted considerable interest from investors.177 
By the time the HGP had been completed, it had cost the government 
$3.8 billion, $2.8 billion of which came from the NIH.178 However, the 
biggest financial payoff from this investment has been in the private sector. 
An estimate by the Battelle Memorial Institute put the amount of economic 
activity generated by the HGP at $67 billion a year, including the steady 
creation of tens of thousands of jobs.179 Genomics-related industries now 
employ about 310,000 workers.180 Battelle pegged the total amount of 
economic output driven by the HGP since its inception at $796 billion and 
the total amount of personal income generated by this output at $244 
billion.181 This financial growth has returned an estimated $49 billion to the 
government in increased tax revenue, $3.7 billion of which was generated 
in 2010 alone.182 
c. The dawn of personalized medicine 
As remarkable as the HGP’s contribution to the private sector has been, 
its most significant returns are yet to come. Based on their understanding of 
the human genome, scientists are learning how to customize drugs to the 
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genetic makeup of individual patients.183 This ability will enable clinicians to 
avoid using drugs that are destined to be ineffective or to produce 
significant adverse reactions in some of these who receive them.184 Many in 
the pharmaceutical industry see the dawn of an era of personalized 
medicine in which products can be tailored to each patient’s metabolic 
needs.185 The clinical potential of this new approach to medication is 
enormous. 
As with much of genomics overall, the initial focus of personalized 
medicine in pharmaceuticals has been in oncology.186 Drugs that treat 
cancer are notorious for the variability of their effectiveness.187 
Chemotherapy agents that achieve miracle remissions in some patients 
leave others with no improvement.188 Physicians have long suspected that 
the genetic makeup of patients, and of their tumors, is crucial to 
determining how they will respond.189 With a genetic profile in hand, they 
can do so. Several targeted drugs have so far been developed for use with 
companion diagnostic tests, including Herceptin for metastatic breast 
cancer, Erbitux for metastatic colorectal cancer, and Gleevec for 
gastrointestinal tumors.190 
Based on the HGP’s map of the genome, new treatments tailored to 
genetic profiles will continue to emerge.191 Eventually, they will replace 
many of the conventional medicines in use today.192 Their introduction will 
transform the scientific and economic foundations of the pharmaceutical 
industry, thanks to a major initiative, the HGP, launched and funded by the 
government. 
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2. National Center for Advancing Translational Sciences 
While there have been many success stories, the bridge between basic 
research and commercial applications can sometimes be difficult to cross. 
With drugs taking up to a decade and by some estimates more than a 
billion dollars on average to bring from concept to market and a failure rate 
of over 95%, pharmaceutical companies often hesitate to commit the 
needed resources when the end result is uncertain.193 This reluctance is most 
often displayed when a drug represents a novel approach to treatment that 
does not yet have a track record, a category that includes most genomic 
drugs.194 As a result, companies have been slower to delve into genetic drug 
development than many medical experts had initially hoped.195 
The pipelines of conventional drugs wending their way through the 
testing and development process began to shrink in the 1990s, and, 
consequently, the rate of FDA approvals for new drugs based on novel 
therapeutic approaches also began to decline.196 Rather than taking the 
chance of achieving breakthroughs in genomics, many companies took the 
opposite course of reducing investments in research.197 At the same time, 
venture capital firms started to hesitate in providing investment capital to 
small biotechnology companies for risky forays into genetics.198 Progress 
toward realizing the full promise of genetic medicine slowed dramatically as 
the industry grappled with the confines of its traditional economic model.199 
For NIH, the hesitation of private industry to commercialize the fruits of 
government-funded basic research represented a threat to its underlying 
mission.200 Historically, the agency has been able to rely on the profit 
potential of new drugs to motivate industry to move drugs from concepts to 
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clinical applications.201 If companies are unable or unwilling to do so, then 
the growing array of NIH-funded scientific discoveries will lie fallow. 
In the reluctance of private companies to commercialize genomics and 
personalized medicine, the agency saw the need to move proactively.202 If 
industry were not in a position to create its future on its own, the government 
would have to do it. For several years, NIH considered ways in which it 
could take the lead in turning genetic discoveries into marketable products. 
In its view, the gap between basic and clinical research required a new form 
of investigation that would translate scientific findings into potential 
applications. This scientific endeavor has come to be called “translational 
research.”203 
The job of stimulating this new kind of scientific inquiry called for novel 
approaches. Starting in the early 2000s, NIH began identifying and 
implementing several of them with the goal of attacking the problem from 
different angles.204 The focus of its efforts was on enticing researchers into 
the new field and providing them with appropriate training.205 To that end, 
NIH funded the “Pioneer Award” to support creative problem solving.206 It 
also devoted funding to facilities and to training of investigators.207 It 
promoted the creation of new resources, like clinical trial networks, 
biospecimen repositories, and molecular screening libraries.208 It also 
considered ways of restructuring itself to better accommodate its emerging 
translational role.209 The first step in this process was to launch a new 
funding program known as “Clinical and Translational Science Awards” to 
promote the development of academic centers to support translational 
work.210 
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The NIH’s bureaucratic reshaping took a dramatic turn in 2010 under 
the directorship of Dr. Francis Collins, who had led the HGP.211 He 
proposed a new center within the agency devoted explicitly to translating 
genomic and other cutting-edge science into clinical applications. The 
National Center for Advancing Translational Sciences (NCATS) was 
conceived that year and implemented in 2011.212 Its mission is to identify 
and remedy “bottlenecks” that stand between scientific discovery and clinical 
applications.213 In Dr. Collins’ view, these arise in large part from the 
novelty of the paradigm for genetic drug development.214 Genomics, he 
believes, has revealed “. . . that the entire framework of medical taxonomy 
requires rethinking and that therapeutics of the future likely will be designed 
with cellular networks in mind, rather than being limited by historical 
designations of disease category.”215 
The biggest bottlenecks lie between the discovery of genes that can 
cause diseases and the initiation of research to test ways to control them.216 
Without an established drug development road to follow, companies are 
reluctant to forge ahead on new ones.217 In a market-based economy, each 
company looks to its own interests. For many pharmaceutical firms that are 
peering ahead at a dramatically altered economic landscape, that means 
limiting exposure to financial risk. The safest course is stand aside and let 
others test the waters.218 This leaves the government as the only entity with 
the mission of protecting larger national interests and the resources to do 
so.219 
NCATS focuses its efforts on the initial steps in the drug development 
process.220 That is the time when drug testing begins, and the process is 
least attractive for private investors, because the chances of success are 
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most uncertain and the expected cost is greatest.221 The new center will carry 
the ball for new drugs through as much of this phase as necessary until a 
private company feels comfortable taking over.222 It will start with preclinical 
studies both in laboratories and in animals and will follow this with testing in 
humans if a drug candidate seems promising.223 If the drug fails, the 
government will have borne the cost. If it succeeds through this phase, the 
chance that it will eventually reach the market is greatly enhanced. At that 
point, the Center will actively seek a private partner.224 
The new center will not try to actually bring new drugs to market. NIH is 
not interested in moving into the commercial sphere.225 The goal is instead 
to create the conditions that enable the competitive market to work in 
bringing genomic therapies to patients as it has in producing traditional 
drugs.226 As the pillar that has supported private pharmaceutical innovation 
for the better part of the past century, NIH stands eager to extend that 
mission into this new terrain. It seems the more scientists learn about the 
way genes function, the more they find they have to learn to apply 
discoveries to the needs of patients. That requires a robust private sector to 
commercialize new products.227 However, the investment in basic 
knowledge that is required is still too great to entice most pharmaceutical 
firms to make the leap.228 The scientific infrastructure does not yet exist to 
translate the new paradigm of biomedical research into a market-based 
business.229 Industry needs the government to create it, and, as it has in so 
many other ways, NIH has taken up the challenge. 
IV.  GOVERNMENT SUPPORT FOR THE PHARMACEUTICAL INDUSTRY BEYOND NIH 
While the role of NIH is invaluable in generating the essential 
intellectual fuel on which the pharmaceutical research engine runs, it is far 
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from being the only major government program that supports and maintains 
the industry. Drug companies depend on a range of other public initiatives, 
both directly and indirectly, for much of their economic viability. A few of 
them illustrate the extensiveness of that reliance. 
A. The Largest Customer for Pharmaceuticals 
Prescription drugs are sold in the United States largely through a private 
market, but it is one that has come to rely almost entirely on third-party 
payment by insurance plans. In 1960, insurance covered 4% of prescription 
drug spending in the United States.230 In 2008, that portion was almost 
80%.231 The most dramatic change occurred during the 1990s, when the 
share increased from 44.5 to 72.3%.232 As the rate of coverage has grown, 
the fraction of insurance represented by private and by public sources has 
remained about the same.233 
In 2008, government programs picked up the tab for $87 billion of the 
$234 billion that Americans spent on outpatient prescription drugs.234 The 
two largest contributors are Medicare at over $55 billion and Medicaid at 
over $25 billion.235 In addition to drugs taken on an outpatient basis, these 
programs also pay billions of dollars a year for drugs administered in 
physicians’ offices and to hospital inpatients.236 
Medicare first covered outpatient prescription drugs in 2006, when Part 
D of the program was launched.237 In 2010, this benefit represented 13.4% 
of the program’s overall budget.238 Medicare covers prescription drugs 
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administered in a physician’s office through Part B and has done so since 
the program’s inception in 1966.239 Additional drug spending comes under 
Part A through payments to hospitals for inpatient care and through several 
other aspects of the program’s coverage, including reimbursement for 
nursing care and for hospital outpatient services.240 
Medicaid has covered outpatient prescription drugs in most states since 
its launch in 1966.241 In 2008, this expenditure represented about 7% of the 
program’s budget nationally.242 In many states, it also represents the fastest 
growing category of spending.243 
Some patients need thousands of dollars a year in prescription drugs.244 
A course of treatment with some oncology medications can cost over 
$100,000 a year.245 These customers would be locked out of the market for 
these lifesaving products were coverage by a third-party payer not 
available.246 By providing the financial means to help patients purchase 
drugs, insurance also increases the size of the potential market for 
pharmaceutical companies and the amounts they can charge for their 
products.247 
Not surprisingly, growth in insurance coverage for prescription drugs has 
tracked growth in overall national drug spending. During the 1990s, when 
the rate of coverage almost doubled, overall prescription expenditures also 
experienced their highest level of growth, almost tripling from $40.3 billion 
to $120.6 billion.248 The trend continued during the early 2000s, when 
Medicare prescription spending rose from $2 billion in 2000 to over $39 
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billion in 2006 with the launch of Part D.249 During these six years, national 
drug expenditures almost doubled, from $120.6 billion to $217 billion.250 
The pharmaceutical industry was robust and profitable long before 
Medicare and Medicaid began covering its products.251 It would 
undoubtedly still have been a major economic presence even without 
them.252 It is also possible that some patients who rely on these programs 
might have been able to find alternative insurance in the private market or 
to pay more of the cost out of their own pockets.253 However, it is unlikely 
that Americans would have been able to come up with $87 billion a year for 
prescriptions on their own.254 Beyond funding the creation of new drugs 
through NIH, the government has positioned itself as the most important 
consumer in the private market through which drugs are sold.255 
B. Quality Assurance Through the FDA 
It is difficult to sell a product if the public has no confidence in it. This is 
all the more true if the product can cause serious injury or death. That is the 
position the pharmaceutical industry is in when it sells medicines that can 
achieve miraculous benefits in some cases but that under some 
circumstances can produce serious harm. 
Americans, by and large, trust the safety of the drugs their doctors 
prescribe.256 There have certainly been instances in which hazardous 
products have reached the market, but most of the time, a vast apparatus of 
quality oversight keeps that from happening.257 The public reassurance that 
this engenders is crucial to sustaining the industry. If patients worried about 
experiencing severe harm every time they filled a prescription, many would 
balk at filling them and many doctors at writing them. 
1. The Growth of FDA Authority Through Scandals 
The source of public trust on which the pharmaceutical market relies 
was almost entirely created and is almost entirely maintained by the 
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government. It begins with oversight of the professions most directly involved 
in bringing drugs to patients.258 Physicians who decide what drugs a patient 
should take do so under licenses granted by the state in which they 
practice.259 Pharmacists who dispense the prescriptions are also licensed by 
their state.260 Licensure provides for a review of basic qualifications before 
these professionals begin practice and for ongoing supervision of their 
quality once they do.261 
However, the greatest source of reassurance for patients is in the quality 
of the drugs themselves, and that is provided by the FDA.262 The agency 
came into being in 1906, a time when pharmaceutical manufacturing could 
hardly be called an industry.263 Drugs were as likely to be sold by a 
physician or compounded by a pharmacist as to be centrally 
manufactured.264 The range of available drugs and their capabilities were 
extremely limited.265 Most of the products that are commonly used today, 
including almost all antibiotics, had yet to be invented.266 The law that 
created the FDA, the Pure Food and Drug Act, was passed after scandals 
involving two popular cold remedies were described in the popular press.267 
Those revelations, along with publication in 1906 of The Jungle by Upton 
Sinclair, which exposed dangerous and unsanitary conditions in the 
meatpacking industry, had undermined public confidence in the food and 
drug supply.268 
Congress expanded the FDA’s authority and created the basic regulatory 
structure that oversees the nation’s drug supply today about 30 years later 
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after another major scandal revealed a serious flaw in the 1906 scheme.269 
The old law had given the FDA authority to pull drugs from the market if 
they were found to be dangerous, and to prevent further sale of them.270 It 
also permitted the agency to block manufacturers from making false claims 
about the composition of their products.271 However, before the FDA could 
act, the product and the claims about it had to have already reached the 
public.272 
In 1937, a dangerous antibiotic preparation entered the market without 
sufficient testing of its safety.273 Elixir of sulfanilamide contained a mixture of 
an antibiotic and a sweet-tasting solvent that made it appealing to 
children.274 The solvent turned out to be highly toxic, with a chemical 
structure that was similar to antifreeze.275 By December of that year, it had 
caused 107 deaths in 15 states, mostly of children.276 The FDA banned the 
manufacturer from selling any more of it, but was only empowered under 
existing law to act after the harm had already been done.277 
Congress tightened the restrictions on drug marketing in 1938 to 
require that the FDA review the safety of new drugs before they could reach 
patients.278 Under new authority granted to it by the Food, Drug, and 
Cosmetic Act, the agency implemented a regulatory scheme under which 
new drugs must undergo years of testing before they may be sold.279 The 
process starts with pre-clinical studies of drug effects in animals and 
continues with three phases of clinical trials.280 
These studies can take eight years or more to complete.281 All of the 
results must be submitted to the FDA for review before a drug can be 
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approved.282 When manufacturing of the drug begins, the agency inspects 
the plants where it will be made for compliance with standards for safety 
and cleanliness.283 It also monitors ongoing use of the drug for signs of 
adverse effects.284 
This new regulatory arrangement averted a public health catastrophe 
about 20 years later. FDA approval was sought for a new drug known as 
thalidomide that was thought to be helpful when taken by pregnant women 
in preventing miscarriages and that also worked as a sleeping pill.285 It had 
already been approved and was widely prescribed in Europe.286 However, 
as use of it spread, so did reports of severe birth defects in the children of 
women who had taken it. By 1962, there had been more than 5,000 such 
reports worldwide.287 In response, the FDA slowed its review process to 
allow more time for information to accumulate.288 The link between 
thalidomide and birth defects eventually became clear and was widely 
reported in the press.289 Before the agency had made a final determination, 
the application for approval was withdrawn.290 
Had the 1938 law not been in effect at the time, the FDA would have 
lacked authority to keep thalidomide off the market while it considered the 
news from Europe of devastating adverse effects. There is no way to know 
how many tragic birth defects would have occurred in the United States 
before the agency could have gathered enough evidence to pull it from the 
market, but it is likely that the number would have been considerable.291 In 
response to this near miss, Congress strengthened the FDA’s authority yet 
again in 1962, this time to require that manufacturers establish a drug’s 
efficacy in addition to its safety before the FDA can permit patients to receive 
it.292 
Additional refinements and enhancements of the FDA’s authority have 
been enacted over the years.293 However, prior review of safety and efficacy 
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remain the primary bases on which it approves new drugs.294 Drug 
companies maintain a massive pre-market testing apparatus to generate 
data to meet the agency’s demands in these regards.295 
2. The FDA Today 
The FDA regulatory apparatus as it exists today is far from perfect. A 
number of drugs have been pulled from the market or subjected to 
heightened warnings years after approval when new safety hazards came to 
light.296 However, incidents of drugs entering the market with unknown and 
devastating side effects are rare.297 Countless drug candidates have been 
blocked before reaching the public because of safety concerns that arise 
during the years of premarket clinical testing.298 At the least, the public 
knows that a tremendous amount of attention has been directed toward the 
safety of the drugs that are prescribed.299 Application of consistent 
regulatory standards also adds stability to the market by reassuring private 
companies and investors that products will be judged through an 
established scientific process.300 
The FDA today is one of the most trusted agencies of the federal 
government. In a 2004 poll, 70% of the respondents reported having either 
a great deal or at least a moderate amount of confidence in it.301 The 
industry often complains about bureaucratic delays and inefficiency in the 
drug approval process, but if patients believed that no one was watching 
over their medications, their willingness to buy the industry’s products would 
be severely compromised.302 The private pharmaceutical market rests on 
such a stamp of approval that only an outside impartial force like the 
government can provide. 
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C. Direct Government Market Support 
The government through the FDA also acts affirmatively to shape the 
private market for pharmaceuticals by developing and sustaining key sectors 
that might not otherwise exist. These efforts guide the market in directions it 
would not have taken on its own. A few of them are particularly influential. 
1. Facilitating Generics to Create Market Competition 
Most importantly, the government has fashioned the competitive 
dynamics of the overall pharmaceutical market by facilitating the entry of 
generic drugs. These are products that include the same active ingredient as 
an existing drug, and they may be sold once the patent on that ingredient 
has expired.303 Generic copies usually sell at much lower prices than the 
original drug and thereby bring an important element of competition to the 
market that can help to control costs.304 
The Hatch-Waxman Act speeds the regulatory approval of generics by 
permitting their manufacturers to piggyback on the results of clinical trials 
for the original patented product.305 Rather than repeating all phases of 
testing, they only have to show that their version is comparable to the 
original in the amount that the body absorbs.306 This means that testing can 
be completed more quickly and cheaply than it would if a full set of trials for 
safety and efficacy were required.307 To speed the process further, testing of 
a generic copy can begin while the original drug’s patent is still in force.308 
With this head start, the generic company can have its product approved 
and ready to be sold as soon as the patent expires.309 
The Hatch-Waxman Act has dramatically reshaped the market for 
generic drugs. In 1984, the year it was passed, generics represented just 
18.6% of American pharmaceutical sales.310 By 1997, that share had grown 
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to 44.3%.311 Today, most prescriptions filled in the United States are for 
generics.312 The ripples of this turnaround have changed the landscape for 
brand name drugs, as well. With the threat of vigorous generic competition 
looming once a patent expires, they can no longer rely on a stock of 
established products to generate profits indefinitely but must continuously fill 
their pipelines with new drugs that have fresh patent clocks. This is a 
competitive force the market would lack were it not for this form of active 
government intervention. 
2. Creating a Market for Orphan Drugs 
Congress authorized the FDA in 1983 to aid drug companies in 
producing medications for rare diseases when it passed the Orphan Drug 
Act.313 Ailments that are extremely rare are known as “orphan diseases”, 
because the small number of patients who suffer from them leaves potential 
treatments with a small potential market that is insufficient to generate 
profits.314 They include numerous conditions that are debilitating and even 
life threatening, such as Huntington’s Disease, myoclonus, Lou Gehrig’s 
disease, Tourette’s syndrome, and muscular dystrophy.315 
The Act authorized grants, tax credits, and seven years of additional 
market exclusivity beyond a patent’s expiration for drugs that are designed 
to treat conditions afflicting fewer than 200,000 people.316 The FDA also 
gives these products special consideration in the approval process.317 With 
this government boost, more than 300 treatments for orphan diseases 
received FDA approval in the 25 years following the law’s enactment, 
compared with only ten during the previous ten years.318 
3. Creating a Market for Pediatric Pharmaceuticals 
Another significant gap in the private pharmaceutical market has been 
the attention paid by major companies to the needs of children. Clinical 
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testing for pediatric drugs can be difficult and risky.319 Children often react 
differently than adults to medications, and adverse effects can be more 
severe.320 To avoid the risks, most clinical trials include only adults as 
subjects.321 As a result, the safety and efficacy of new drugs when used to 
treat children are rarely known with accuracy when they are first 
approved.322 
Pediatric testing often does not make financial sense for private 
companies because of the relatively small portion of the market involved, 
but there is still a significant need to determine how children will react to 
new drugs.323 To remedy this gap in market incentives, Congress in 1997 
authorized special incentives to encourage companies to conduct clinical 
trials in children in the form of FDAMA.324 That law offered companies a 
reward of six months of additional market exclusivity after a patent expires 
for drugs that have undergone pediatric testing.325 In 1999, the FDA issued 
a related regulation known as the Pediatric Rule, under which it requires 
companies to test some new drugs in children.326 The Act and the regulation 
are together credited with inducing companies to conduct a substantial 
number of pediatric studies, thereby expanding the clinical uses as well as 
the market for many pharmaceutical products.327 
4. The FDA and the Future of Genomic Medicine 
FDA’s role in promoting generic drugs, orphan drugs, and pediatric 
testing of new drugs arose from directives of Congress. In 2010, without 
waiting for new legislation, the agency acted on its own initiative to reshape 
the private market in another important area. It took steps to prod 
pharmaceutical companies to respond to the challenge of commercializing 
genomic medicine. It did so in partnership with NIH as part of an effort to 
facilitate the advance of translational science.328 Under this arrangement, 
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NIH promotes research and training, while FDA encourages companies to 
integrate genomics into their drug development processes.329 To that end, it 
tries to coordinate the review of genetic diagnostic tests that predict 
responsiveness to drugs with review of the drugs themselves.330 The goal is 
to facilitate the development of diagnostic-therapeutic combination 
approaches that aid clinicians, along with a review process that reassures 
companies that new technologies in which they invest will receive prompt 
review.331 
The NIH-FDA partnership builds on NIH’s translational medicine 
initiative that extends the government infrastructure on which the nascent 
market for genomic medicine rests.332 In doing so, it will help to promote an 
even larger and more robust private pharmaceutical industry. The agencies 
acted in the belief that the market will not grow on its own but rather 
requires assistance from its indispensable partner, the government. In a joint 
statement, the heads of the agencies described the model they created as a 
logical extension of the paradigm on which so much of American industry is 
built: 
When the federal government created the national highway system, it did 
not tell people where to drive — it built the roads and set the standards for 
safety. Those investments supported a revolution in transportation, 
commerce, and personal mobility. We are now building a national highway 
system for personalized medicine, with substantial investments in 
infrastructure and standards.333 
D. More Government Subsidies Through Tax Breaks 
In addition to these forms of regulatory support and funding for the 
infrastructure on which their research apparatus rests, the government also 
lends drug companies assistance of a more direct kind. It gives them money 
in the form of tax credits.334 This financial boost lets pharmaceutical firms 
lower their tax bills, and thereby keep more of their income, by devoting 
resources to research.335 While the nature of the credits has changed over 
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time with amendments to the federal tax code, the underlying mechanism of 
paying private companies to conduct research has remained.336 
Three kinds of tax credit are available to companies. A research and 
experimentation credit allows companies to lower their taxes in return for 
increasing the amount they spend on in-house research.337 A basic research 
credit encourages companies to fund scientific investigations at 
universities.338 An orphan drug credit rewards the development of drugs for 
rare diseases as part of the Orphan Drug Act.339 
These inducements, worth more than $5 billion a year, do not 
significantly alter the nature of the industry, and the benefits tend to accrue 
mainly to larger companies.340 However, they help to encourage the overall 
growth of the private research enterprise.341 In doing so, they form yet 
another government platform that has helped the private market to flourish. 
E. The Most Fundamental Government Support of All:  Patents 
Beneath the billions of dollars and intricate web of laws and regulations 
that comprise the government’s active intervention to create and sustain the 
private pharmaceutical market lies an even more fundamental pillar. That is 
the protection that patent laws confer on its products. Without these laws, 
the industry could not exist in anything close to its present form. 
Patents grant inventors 20 years from the date of filing to prevent 
anyone else from manufacturing, distributing, or selling their inventions.342 
In effect, inventors enjoy a monopoly during this time and can take 
advantage of the lack of competition to set prices above those that a free 
market would sustain.343 The actual amount of time during which drugs can 
be marketed exclusively under a patent is less than the full 20 years in 
practice, because clinical testing and FDA review can eat up as much as 
half of the full patent term.344 However, the time remaining once marketing 
has begun has been more than sufficient to support ample profits for most 
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products.345 Moreover, the exclusive sales period is often extended by other 
laws, such as the Hatch-Waxman Act and FDAMA.346 
The exclusive marketing protection granted by patents is vital to the 
pharmaceutical industry. Companies rely on patent protection as the 
bedrock of their economic model.347 Monopoly prices allow them to recoup 
research and development costs for new products, amass funds to 
investigate novel therapies that may not make it to market, and generate 
substantial financial returns.348 These prices provide the economic 
underpinning for the emergence of blockbuster drugs that bring companies 
billions of dollars in sales each year.349 
The law of patents is rooted in the United States Constitution, which 
authorizes Congress to protect property rights in inventions.350 The patent 
system that Congress established to effectuate this constitutional directive is 
administered by the USPTO, which decides whether inventions meet the 
criteria for patentability.351 Patents were not included in the Constitution or 
implemented by Congress with the pharmaceutical industry specifically in 
mind.352 Rather, they form a key underpinning of our entire economic 
system.353 Nevertheless, their application to drugs forms an indispensable 
part of the infrastructure that supports private pharmaceutical companies. 
Without this government foundation, the industry would take on a very 
different, and almost surely less profitable, form. 
V.  GOVERNMENT SUPPORT IN ACTION:  CASE STUDIES OF MEDICAL MIRACLES 
Whether they realize it or not, everyone who has taken a prescription 
drug in the past 50 years has experienced the effects of public-private 
collaborations first hand. It would be difficult to identify a medication 
developed during that time that did not emerge from a base of at least 
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some government-funded research. Medications for high blood pressure, 
high cholesterol, cancer, depression, and Parkinson’s disease, to name just 
a few examples, grew out of government-funded research findings.354 Along 
with the success of these drugs have ridden the financial fortunes of many 
major pharmaceutical firms. 
Prime examples of successful public-private drug development sit inside 
the medicine cabinets of millions of Americans. Two of them illustrate 
especially poignantly the importance of the partnership between NIH-funded 
discoveries and industry commercialization. One reflects an ad hoc 
relationship, in which a collaboration evolved over time. The other emerged 
from an explicit effort by NIH to identify and work with a corporate ally. 
A. The Traditional Model:  The Story of Statins 
Some drug success stories start without a clear plan. A discovery in basic 
research leads a private firm to devise a potential application that it 
investigates in its laboratories.355 Others are more haphazard. A firm may 
screen thousands of compounds hoping that one of them shows commercial 
promise based on directions identified in prior research.356 Whatever the 
approach, in conventional drug development, private industry takes the 
laboring oar in vetting drug candidates, after government-funded basic 
research has pointed it in promising directions.357 The development of one 
of the most widely prescribed classes of drugs — statins — vividly tells the 
tale. 
A complex public-private partnership that evolved over the course of 
several decades led to the development of statins, which today are among 
the most important pharmacological therapies in medical practice.358 These 
drugs are used by millions of people worldwide to reduce blood cholesterol 
levels.359 They have proven extremely effective at preventing heart attacks, 
strokes and other heart-related ailments among those with high cholesterol 
or other risk factors such as diabetes.360 Heart disease is the most common 
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cause of death in the United States and around the world, and much of it is 
caused by the build-up of plaque composed of cholesterol in the arteries.361 
In preventing heart-related ailments, statins have saved millions of lives 
since they first appeared on the market in the late 1980s.362 
Because of their effectiveness at forestalling the most common deadly 
condition on Earth, statins have also come to represent a powerful financial 
force in the pharmaceutical industry. In 2006, physicians wrote an average 
of 13.1 million statin prescriptions each month.363 One of them, Lipitor, was 
the most widely prescribed drug in the United States for several years.364 In 
2005, it generated $16 billion in sales derived from 144.5 million 
prescriptions.365 
1. The Link Between Cholesterol and Heart Disease 
The link between cholesterol and heart disease was first noted over 100 
years ago.366 Dr. Rudolf Virchow, a German pathologist, observed on 
autopsy that patients who died of vascular conditions in which the arteries 
were narrowed, like heart attacks, often had thickened and irregular artery 
walls.367 He found that the arterial walls in these patients were coated with a 
yellowish fatty substance, which he identified as cholesterol.368 Dr. Virchow 
was not able to explain the role of cholesterol in the pathological changes 
he observed in artery walls or how it gets there, but he raised the intriguing 
possibility that this kind of fat could be connected with heart disease.369 
The first clear evidence of an association between high levels of blood 
cholesterol and the buildup of plaque in artery walls came from a large 
long-term epidemiological investigation of risk factors for heart disease 
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known as the Framingham Heart Study.370 That research involved a massive 
effort to follow over ten thousand residents of Framingham, Massachusetts 
starting in 1948 to observe changes in a range of physiological markers 
and health outcomes over time.371 In the 1960s, results of the research 
began pointing to high levels of serum cholesterol as a key culprit in the 
narrowing of arterial walls that could be a precursor to heart attacks.372 
The Framingham Heart Study was the most extensive epidemiological 
investigation to that time.373 The thousands of study participants received 
thorough physical examinations and extensive blood testing on an annual 
basis over the course of decades, with a cost that reached tens of millions of 
dollars.374 When the project began, the benefits of this huge investment 
were largely speculative, as it was not possible to predict what the study 
would actually find.375 This was an ideal project for government sponsorship 
through NIH. 
The government’s support for the study paid off handsomely. The most 
widely acknowledged result is the identification of high cholesterol as a 
major cause of cardiac disease, but it also identified over ten other risk 
factors, including salt intake and smoking.376 Much of what is known today 
about heart disease and its prevention stems from this seminal research.377 
2. The Hunt for a Way to Lower Blood Cholesterol 
Once the Framingham Heart Study had fingered cholesterol as a 
potential killer, basic research into its molecular composition began in 
earnest. Scientists were particularly interested in figuring out how it is 
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synthesized in the body.378 Blood cholesterol can come from both external 
and internal sources. It enters the body from the outside through dietary 
intake of fatty foods.379 It is produced internally through synthesis in the 
liver.380 Dietary changes alone are often effective in reducing a patient’s 
blood level, but when they are not, controlling cholesterol’s internal 
manufacture represents the most likely alternative approach.381 
Research to explore the body’s mechanisms of cholesterol synthesis was 
conducted by scientists starting in the 1940s at several universities, including 
Harvard, UCLA, the Max Planck Institute in Munich, and the National 
Institute for Medical Research in London.382 NIH funded most of the 
research that was carried out in the United States.383 The results of this work 
delineated the steps that lead to the liver’s manufacture of cholesterol and 
identified a way to disrupt the process by blocking the action of a key 
enzyme, hydroxymethyl glutaryl coenzyme A reductase, known as HMG-CoA 
reductase for short.384 The findings set the stage for a search for drugs that 
might serve this function. 
The first challenge in finding a drug candidate was to locate a reliable 
source of the enzyme to use in tests.385 In 1960, a method was devised for 
isolating it from baker’s yeast, along with a test to determine whether a drug 
candidate was effective at inhibiting its activity.386 These techniques were 
based on technologies that had been developed in the 1950s with support 
from NIH and the National Science Foundation (NSF), another federal 
agency that funds basic science research.387 
With the technology in place to conduct the search, the hunt began for 
inhibitor molecules. In the early 1970s, it peaked the interest of private 
pharmaceutical firms. One company in particular, Sankyo Pharmaceuticals 
in Japan, devised a method for evaluating molecular candidates in 
molds.388 In 1976, it found one in a species related to the strain of mold 
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that produced penicillin and gave it the name compactin.389 However, to 
test it on a large scale, sufficient quantities had to be produced.390 This was 
accomplished using technologies that had, again, been developed with 
support from NIH and NSF.391 These included x-ray crystallography and 
infrared and NMR spectroscopy, which are used in a range of different kinds 
of basic and applied research.392 
3. A Private Manufacturer Tests the Waters 
With the identification of a molecule that could block the liver’s synthesis 
of cholesterol and the refinement of techniques to produce it in large 
quantities, the next step was for a pharmaceutical company to try to bring a 
product to market. The first to take up the challenge was Merck.393 
However, even in this commercial endeavor, it was only by collaborating 
with the government that success was achieved.394 
In 1979, scientists at Merck isolated an inhibitor molecule that seemed 
a likely drug candidate, a substance known as lovastatin that is similar to 
compactin.395 The company soon initiated clinical trials to examine its safety 
and effectiveness.396 Unfortunately for the effort, at about this time, the 
World Health Organization reported results of a clinical trial of another new 
lipid lowering drug, and they were extremely disappointing.397 There was 
actually a higher mortality rate for patients on the drug than for those on a 
placebo.398 Then in 1980, Merck received reports suggesting that 
compactin could cause cancer in dogs.399 The company’s CEO, P. Roy 
Vagelos, who had strongly championed the quest for a cholesterol blocker, 
decided to terminate the clinical trials.400 
With the private sector faltering in the quest for what promised to be a 
miracle drug, the government decided to step back in. Officials at the FDA 
began working with Merck to help it to restart its efforts.401 While some see 
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the agency as a barrier that slows the process of drug development, in this 
case it was the instigator that kept the process going. The FDA convinced 
Merck to make lovastatin available to researchers at Oregon Health 
Sciences University and at the University of Texas.402 Once these supplies 
were in the hands of academic researchers, the agency granted them 
permission to conduct new trials in human subjects.403 Merck also agreed to 
grant the investigators access to the drug’s master file, the collection of 
public and proprietary information on it that the company had accumulated 
and that was maintained by the FDA.404 
In 1984, the gloom surrounding the prospects for statins started to lift 
with encouraging news on two fronts. Results of a large clinical trial released 
that year showed that cholesterol lowering by any means, whether dietary 
changes or medications, could produce a significant drop in heart disease 
and death.405 And new genetic research on patients with high cholesterol 
succeeded in elucidating the means by which the most dangerous kind of 
cholesterol, LDL, is disposed of by the liver.406 The scientists who made that 
discovery, Dr. Michael Brown and Dr. Joseph Goldstein, were awarded the 
Nobel Prize the following year.407 
With prospects looking up for lowering cholesterol pharmacologically 
based on the university-based research, Merck revived its own work on 
lovastatin in 1983.408 It was not long before the company had accumulated 
enough data to submit an application to the FDA for approval to market the 
drug.409 The agency took only nine months to act on lovastatin, one of the 
shortest approval times up to that point.410 Once the FDA had acted, Merck 
began marketing lovastatin under the brand name Mevacor in 1987.411 It 
brought another statin, simvastatin, to the market at about the same time 
under the name Zocor.412 By 1998, sales of Zocor had reached $4.7 billion 
worldwide.413 
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Other drug companies soon got into the act, and over the next few 
years, several additional statins reached the market. These included Lipitor, 
from the Parke-Davis division of Warner Lambert, now a part of Pfizer, 
Pravacol from Sankyo and Bristol-Myers Squibb, and Lescol from 
Novartis.414 Most of these products became blockbuster drugs, generating 
more than $1 billion in annual sales and serving as financial anchors for the 
companies that sold them.415 
4. The Next Generation of Statins 
Even with this remarkable clinical and economic success, work to 
improve the effectiveness of statins continued. Scientists were especially 
interested in finding new inhibitors of cholesterol synthesis that might be 
easier to produce in large quantities.416 That work relied heavily on 
computer graphics programs developed at the University of California at 
San Diego that permitted researchers to visualize and manipulate the three-
dimensional structure of molecules.417 Previous methods of testing new drug 
candidates had required that they actually be synthesized, a much more 
expensive and time-consuming process.418 Computer graphics allowed 
molecules to be vetted based on computational models.419 The software 
behind this capability grew out of research funded by NSF and the 
Department of Defense.420 It led to the creation of new statins that were 
simpler in structure and substantially cheaper to produce, including 
fluvastatin by Sandoz and atorvastatin by the Parke-Davis division of 
Warner-Lambert.421 
Statins today are a mainstay of cardiac care and prevention. Over one-
quarter of all Americans over the age of 45 take them.422 They generate 
more than $30 billion in sales worldwide.423 Lipitor has not only been the 
top selling drug in the world for several years but is also the world’s all-time 
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best-selling prescription drug with cumulative sales of more than $130 
billion.424 
Aside from their staggering economic success, statins are remarkable 
drugs clinically. They substantially reduce the risk of serious cardiac events, 
including heart attacks, an accomplishment that had only been dreamed of 
in the years before they were developed.425 They have saved countless lives 
and incalculable costs for treating heart conditions that would otherwise 
have arisen.426 These medical results have led to a financial bonanza for 
several pharmaceutical companies in a robust private market that would not 
exist without the active hand of the government.427 
B. The Formal Approach:  A Miracle in the Woods and the Development of 
Taxol 
Statins emerged from accumulations of basic research that built up over 
time and increasingly pointed to clinical applications.428 Collaborations 
between the public and private sectors that produced the final products 
evolved as the discoveries emerged. The arrangements were sometimes 
implicit and occasionally spontaneous. 
Other drugs emerge from explicit partnerships between the government 
and private companies, most commonly in the form of CRADAs. Perhaps the 
most prominent example of a success in such an explicit collaboration is the 
development of Taxol, the best-selling cancer drug in history.429 It has 
extended the lives of thousands of woman suffering from ovarian and breast 
cancer and would never have been invented but for decades of effort by 
government scientists and millions of dollars of investment by government 
agencies.430 
1. A Search in the Forest 
In 1962, Arthur Barclay, a botanist working for the United States 
Department of Agriculture (USDA), began an innovative field project in the 
Gifford Pinchot National Forest near the town Packwood, Washington, close 
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to Mount St. Helens.431 His work was part of an effort to explore the region’s 
flora for medicinal properties.432 The investigations led him to focus on the 
Pacific Yew tree, the bark of which he suspected of having a range of 
biological effects.433 
Acting on his suspicions, Barclay collected and dried samples of the Yew 
Tree’s bark and sent some to a laboratory of the USDA located in 
Maryland.434 Researchers there and at NCI, a component of NIH, had 
become interested in screening naturally occurring chemicals as agents to 
fight cancer, and the agencies had entered into an agreement a few years 
earlier to cooperate in vetting plant samples.435 The scientists tested 
Barclay’s samples for a range of possible effects, and the results confirmed 
his initial conjecture concerning the value of Yew bark.436 One of the tests 
revealed significant activity in inhibiting cancer cell cultures.437 
Over the next several decades, Barclay’s find came to revolutionize 
treatment for certain types of breast and ovarian cancer.438 The fruits of his 
work today take the form of the drug paclitaxel, which is sold under the 
brand name Taxol.439 Many consider it a wonder drug, and it is credited 
with extending the lives of thousands of cancer patients.440 It was later 
discovered to have another, seemingly unrelated medical use as the coating 
for cardiac stents that hold open clogged arteries in patients with heart 
disease.441 
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2. Public-Private Collaboration to Produce a Drug 
The story of Taxol is a tale of different sectors of the country’s scientific 
enterprise working together under the structure that Congress had 
developed to promote such cooperation. After USDA’s initial finding of 
Taxol’s potential anti-carcinogenic effects, efforts began in earnest to isolate 
the active compound involved.442 Research was conducted within USDA, at 
NCI, and at several universities and private research institutes supported by 
NIH grants.443 In 1971, after almost a decade of effort, Drs. Monroe Wall 
and M.D. Wani of Research Triangle Institute announced that they had 
identified the chemical structure of the seemingly miraculous substance.444 
In 1979, researchers at the Albert Einstein College of Medicine in New York 
delineated the mechanism through which it works.445 
NCI received permission from the FDA to begin clinical trials of the drug 
in 1982.446 As these studies progressed through the 1980s, they increasingly 
pointed to effectiveness in treating the disease.447 Final results for the second 
phase of the clinical trials were released in 1988 and showed a response 
rate of 30% among patients with the most virulent form of ovarian 
cancer.448 In some tests, the rate was as high as 60%.449 Such positive 
findings were unprecedented for an anti-cancer agent.450 
Not surprisingly, Taxol’s success led to a surge in demand for it.451 
However, sufficient supplies were difficult to come by. The original process 
for extracting Taxol required between 10,000 and 30,000 pounds of dried 
bark to produce one kilogram of the drug.452 NCI estimated that in order to 
treat all the ovarian cancer patients who needed Taxol, 360,000 yew trees 
would have to be harvested every year, which made its use impractical.453 
The answer was to create a synthetic version, and scientists in the United 
States, Asia and Europe labored through the 1980s toward this goal.454 
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Success was achieved in 1989, when researchers at Florida State University 
(FSU), funded by NIH, developed a process for Taxol’s semisynthesis.455 
Their technique did not permit manufacture to be completed from scratch, 
but it enabled partial synthesis of the active ingredient.456 Of particular 
importance for insuring future supplies, the raw material for the process 
came from a different type of yew tree that grew in much greater abundance 
than the one that had originally been used.457 
The decades of effort paid off handsomely. By 1989, the government, 
though USDA and NCI, had discovered paclitaxel in the forests of the 
Northwest, isolated it, and established its clinical utility. An academic 
partner, FSU, had found a way to manufacture it without causing massive 
deforestation. With this much accomplished, NCI saw its role dwindling. It 
had spent over $25 million and did not have the resources for the next step, 
which was to produce the synthetic compound in sufficient quantities to be 
brought to market for large numbers of patients.458 The government needed 
a partner with the wherewithal to meet this challenge. 
3. Bringing a Product to Market 
In 1989, soon after FSU’s successful synthesis of paclitaxel, NCI 
solicited interest from pharmaceutical companies to enter into a CRADA to 
commercialize it.459 Of the four that responded, one stood out as the most 
prepared for the task, Bristol-Myers Squibb (BMS).460 In addition to extensive 
experience with oncology products, BMS had a track record of successful 
collaboration with the federal government in the development of an early 
treatment for AIDS.461 To NCI, the company seemed the natural choice, and 
in 1991, it selected BMS for a CRADA to bring paclitaxel to market.462 The 
CRADA turned out to be one of the first to result in wide availability of a 
breakthrough drug.463 
Soon after NCI announced its search for a CRADA partner but before 
the agreement had been finalized, BMS began to explore Taxol’s 
potential.464 It obtained a license to use FSU’s technique for semisynthesis of 
the drug the following year.465 The license also applied prospectively to any 
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refinements of the technology that FSU might produce, and in 1992 BMS 
gained the right to use a greatly improved semisynthesis technique that 
yielded a much larger quantity of Taxol’s active ingredient.466 This 
corporate-academic partnership came to benefit both parties handsomely. 
BMS gained the ability to market an extremely lucrative drug, and FSU 
received over $200 million of dollars in royalties, among the largest 
financial paybacks that any university had received from a technology 
transfer agreement up to that time.467 
During the early years of testing, NIH performed or funded most of the 
clinical trials on Taxol.468 BMS supplied the drug to NIH researchers to 
facilitate the trials, which had been in short supply.469 Over the course of the 
CRADA, the number of research subjects participating rose from about 500 
in 1989 to 28,882 at over 40 treatment centers.470 This led to a faster pace 
of testing, which enabled BMS to speed the process.471 It received approval 
from the FDA to market Taxol for treating ovarian cancer in December 
1992, and the drug began reaching patients the following month.472 
NIH invested a considerable amount of resources in the development 
and testing of Taxol both during the CRADA and after it had expired.473 The 
total value of its investment before the CRADA’s expiration is estimated at 
$183 million.474 In the five years after the CRADA expired in 1997, it spent 
an additional $301 million, placing the total NIH investment at $484 
million.475 BMS provided a partial offset by supplying NIH with supplies of 
the drug valued at $92 million for use in the trials.476 
BMS estimates that for its part, it spent about $1 billion in developing 
Taxol.477 The return on this investment was more than adequate. By 1994, 
the drug had reached the market in 50 countries.478 In 1998, sales stood at 
$1.2 billion, and in 2000, they peaked at $1.6 billion.479 Through 2002, 
cumulative sales topped $11 billion after rising by an average of 38% a 
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year.480 These rewards reflected both the large demand and the high price 
that BMS was able to charge. In 1993, a single gram of Taxol cost 
$5,846.481 
On its revenues, BMS owed NIH a royalty of 0.5% based on a license 
agreement that had been reached in 1996.482 The resulting payments 
totaled $35 million.483 While this was a tiny amount compared to BMS’s 
overall returns on the drug, it was enough to repay a sizeable share of the 
government’s investment.484 
BMS owed some of its return on Taxol to another government source.485 
Public insurance in the form of Medicare covered the cost of the drug for 
most elderly patients.486 Reimbursement totaled $687 million from 1994 to 
1999, the year that a generic version of Taxol was approved.487 And in 
1999, Medicare payments represented over one-fifth of the drug’s domestic 
sales.488 
4. Public-Private Bargaining Over Finances 
BMS entered the negotiations that led to the CRADA in a strong 
bargaining position. NIH needed an industry partner that could bring an 
adequate supply of Taxol to market.489 When the CRADA was created in 
1991, the drug was in short supply, which made clinical testing difficult.490 
None of the other companies that had responded to NIH’s solicitation of 
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interest ranked close to BMS in the capability to supply the drug.491 The 
agency could have sought multiple partners, since CRADAs do not have to 
be exclusive, but this would have made the arrangement much less 
attractive to private partners.492 NIH also wanted to act quickly, as the drug 
promised lifesaving benefits to dying patients.493 
NIH’s bargaining position was further limited by its inability to transfer 
rights to an actual patent.494 Taxol did not qualify for patent protection 
because by the time NIH was able to file a patent application, information 
about the drug had already entered the public domain.495 This negated the 
substance’s status as “novel,” a key requirement for patentability.496 The 
prize it had to offer to a CRADA partner was instead access to research 
findings developed before and during the agreement.497 In lieu of a patent, 
BMS received five years of marketing exclusivity after FDA approval of its 
Taxol application.498 This functioned as the equivalent of patent protection 
by preventing a competitor from gaining permission to sell the same 
product.499 Generic paclatxel received full FDA approval for marketing in 
2000, although its status remained subject to litigation until 2002.500 
As a result of the mismatch in bargaining strength, NIH received a rather 
meager level of royalties for a lifesaving drug that it was largely responsible 
for developing.501 The agency is often constrained in CRADA negotiations 
by limited competition for participation among qualified drug companies.502 
It is unusual for more than one to express interest in a particular licensing 
arrangement.503 In about 30% of cases, NIH receives no expressions of 
interest at all.504 The result is that low royalties, such as the 0.5% rate 
negotiated with BMS, are not uncommon.505 However, the immediate 
financial return to the government is a secondary concern for policy makers. 
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The central goal is to harness the innovation and drive of private companies 
to bring promising new technologies to patients.506 
5. An Additional Lifesaving Use 
The success of the CRADA between NIH and BMS was only part of the 
story. Beyond the value of paclitaxel in treating cancer, the drug also found 
an important use in cardiac care.507 After the oncology benefits had been 
established, researchers discovered that it discourages the growth of scar 
tissue around the sites of metal stents that are inserted into clogged arteries 
to prop them open.508 Scarring can lead to the re-deposit of clog-inducing 
plaque.509 
This second use of paclitaxel was again the offshoot of a government 
effort, as the initial research was conducted by two scientists working at 
NIH.510 Based on the finding of value in protecting the sites of cardiac 
stents, the agency entered into a CRADA with a company called Angiotech 
to commercialize this use of the drug.511 Angiotech sublicensed its rights to 
Boston Scientific, which applied for FDA approval to market paclitaxel for 
coating cardiac stents under the name TAXUS.512 The path to approval was 
eased by the drug’s safety record in the previous clinical trials involving 
cancer treatment.513 The product was approved for the new use, and it went 
on to become a clinical and commercial success, with millions of paclitaxel-
coated stents sold worldwide and generating sales of over $3 billion.514 
6. Paclitaxel and Public Policy 
Paclitaxel is an example of a technology for which the CRADA system 
worked as its Congressional designers had intended. The government 
created the conditions that let the private market carry the ball in bringing a 
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clinically important drug to patients. Through a series of laws that 
encouraged public-private collaboration and an initial government-funded 
research effort, a previously unknown substance emerged from the woods of 
the Pacific Northwest to become a life-saving product. The effort produced 
huge financial rewards for a drug company, a device company, and a 
university that played an instrumental role in its development. Most 
importantly, it has extended the lives of millions of patients around the 
world. 
C. The Next Era in Drug Development and the Promise of More Success 
Stories 
A new era in drug development dawned in the 1990s thanks to a new 
approach called combinatorial chemistry.515 It permits scientists to create 
libraries of thousands of compounds that can be tested as candidates to 
perform specific functions, like inhibiting HMG CoA reductase in the liver to 
block the synthesis of cholesterol.516 Within the time span of a few months, 
millions of such candidates can be tested for efficacy, a level of efficiency 
that was not previously possible.517 
The new approach has begun to revolutionize private drug 
development. It is now the principal method for finding new medications of 
every kind, and it yields results with dramatic new speed.518 By way of 
comparison, the old technology had enabled Merck to synthesize, purify and 
screen about 250,000 different chemicals in the 60 years between 1934 
and 1994.519 In the four years between 1995 and 1999, using 
combinatorial chemistry techniques, it synthesized and tested 4.5 million.520 
Like so many other technological advances that have bolstered the 
financial prospects of private pharmaceutical companies, combinatorial 
chemistry was devised by scientists who relied on NIH for financial 
support.521 Beyond the pharmaceutical manufacturers that use it, a 
burgeoning new industry now supports its application. A raft of companies 
provides instrumentation, chemical re-agents, and software.522 Through 
them, the government investment in advancing the process of drug 
development has sent ripples through a large swath of the private sector.523 
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VI.  THE “FREE-MARKET” PHARMACEUTICAL INDUSTRY AND THE GOVERNMENT 
A. What Would the Industry Look Like Without the Government? 
Let us turn to the fundamental question that underlies this article.  How 
did the pharmaceutical industry, which has remained among the most 
profitable for decades, get that way? Certainly, entrepreneurship and 
innovation played a tremendously important part in maintaining the 
robustness of drug companies over the years. Market forces continuously 
prod private companies to devise new products and stay ahead of the 
competition. However, those companies must have raw materials to work 
with in their intellectual arsenal. For pharmaceutical firms, that is basic 
knowledge of human biology. Over the past three-quarters of a century, the 
greatest producer of that knowledge by far has been the United States 
government. 
We can highlight the government’s role in creating and maintaining the 
pharmaceutical industry by asking what the industry would look like without 
its government base. Without question, it would still exist. Pharmaceuticals 
date back almost as far as recorded history.524 Ancient Egyptian writings 
describe pharmaceutical preparations, as do the records of almost every 
early civilization.525 Private companies, as well as individuals, have been 
manufacturing drug products since colonial times in America, long before 
there was an NIH to support research or an FDA to oversee quality.526 
But what would that industry look like without the pillars of government 
support that emerged in the twentieth century? It would almost certainly be a 
shadow of its present self. Virtually every major drug that has supported 
private pharmaceutical profits over the past 50 years was developed with 
government support in one form or another. In no field of medicine would 
available treatments approach the range or effectiveness that they do today. 
Imagine cardiac care without statins, oncology care without paclitaxel, or 
care for AIDS without AZT. In fact, it is impossible to name any medical 
specialty that does not today depend for its pharmacological tools, in some 
cases almost entirely, on investment by the government and the innovation it 
spawned. 
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B. Could Private Industry Have Made It on Its Own? 
We know what the government has contributed, but it would also be fair 
to ask whether the industry might have accomplished these or similar 
advances on its own. Without NIH, might private entrepreneurs have 
mustered the resources to meet the basic science challenges that created 
modern medicine? Perhaps the same market forces that promote applied 
research in bringing products to market could have supported the advances 
in biology that underlie it. 
To answer that question, we can look to the stories behind some of the 
most important fruits of government intervention. Merck was ready to give 
up on statins before NIH and the FDA stepped in with a helping hand.527 
Government scientists combed the forests of the Pacific Northwest in search 
of anti-carcinogens, eventually discovering paclitaxel, at a time when private 
companies showed little interest.528 And beyond these examples, the 
development of countless other drugs tells a similar tale.529 
As we look to the future of medicine, we can ask whether any private 
company could have devoted the resources to mapping the human 
genome, the essential first step in opening the door to genetic medicine. The 
investment required was huge and the knowledge gained will require 
decades to commercialize. Moreover, its findings are public information 
available to everyone, including competing companies, to take advantage 
of.530 What private investors would have allowed their funds to be used in 
this way? 
C. Has the Government Acted Wisely? 
Government support for the pharmaceutical industry has its share of 
critics. Many see the large amounts of money that are given as an 
undeserved subsidy for an industry that could be amply profitable on its 
own.531 They point in particular to companies that patent discoveries based 
on NIH-funded research, thereby staking an ownership claim in a publicly 
funded resource.532 They ask why private ventures should be allowed to reap 
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such rewards, when taxpayers supported the underlying scientific 
advances.533 
CRADAs can result in particularly disproportionate returns for private 
participants. In the case of Taxol, NIH received $35 million on behalf of 
taxpayers under a licensing agreement with BMS after spending almost 
$500 million to test the drug.534 By the time it first faced generic 
competition, BMS had earned over $11 billion.535 The company claimed 
that it invested $1 billion of its own money in applied research to bring 
Taxol to market, but even with this expense, its rate of return dwarfed that of 
NIH.536 Is it fair that a private entity should profit so handsomely from an 
invention that would not have been possible without substantial government 
investment? 
Tax subsidies for research and development often come in for especially 
harsh criticism.537 Do highly profitable companies really need a subsidy to 
invest in research, when they would have to make the investment anyway to 
remain competitive? Perhaps the government already gives the industry 
enough research support through NIH. 
FDA oversight of safety is also often questioned as too lax.538 Several 
drugs with dangerous side effects have slipped through the vetting process, 
sometimes after receiving accelerated review.539 The result has been recalls 
and additional warnings after reports of patient harm.540 Vioxx, for example, 
was approved on an expedited basis as a treatment for arthritic pain, and its 
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review failed to spot long-term cardiac hazards that a more deliberative 
process might have revealed.541 
Perhaps taxpayers could be getting a better deal from their investment in 
the private pharmaceutical industry. The system of support could 
undoubtedly be improved in many ways. However, whatever the optimal 
level of support, government investment has over the years been, and 
remains today, crucial to the industry’s wellbeing. Whatever shortcomings 
the system may have, we have clearly gotten a robust and highly profitable 
set of companies and a cascade of new drugs in return for the government’s 
involvement. The pharmaceutical industry would not exist in the form it takes 
today, with all of its accomplishments and faults, but for a hundred years of 
government intervention. 
D. Conclusion: Public Investment and Private Industry 
Pharmaceuticals are developed, manufactured, sold, and distributed in 
the United States through the private sector. Private investment and 
competition among firms drive the sector’s economics. These dynamics 
characterize what is typically thought of as a “free-market.” However, the 
market does not exist because the government stepped aside and let private 
enterprise operate without constraint. Quite to the contrary, it operates 
precisely because the government has insinuated itself into almost every 
aspect of the business. 
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